

Form approval date:
OMB Control Number: 0920-1282
Expiration date: 1/31/2023

Public reporting burden of this collection of information is estimated to average 10 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; Attn: OMB-PRA (0920-1282).

Global Covid19 Metrics Report

Reporting Period: FY22 Q1-Q2 (1 October 2021 - 31 March 2022)

Reporting Deadline: May 11, 2022

Instructions: Each implementing partner should complete one metrics report (e.g., REDCap form) for each country, and for each cooperative agreement where funds are provided to support COVID-19 activities in one or more of the eight technical areas. If you provide support for multiple technical areas within one country, complete the reporting for each supported technical area within one REDCap form per cooperative agreement. If you are funded to work across multiple countries, complete a REDCap form for each country, and each cooperative agreement within the respective country.

Please refer to the Program Implementation Indicator Reporting Guidance and/or the Indicator Reference Sheet for a detailed description of the indicators and guidance on completing the form.

Please DO NOT complete the data collection form if you have NOT started implementation activities.

IMPORTANT: New this reporting period are Key Performance Indicators (KPIs), which are highlighted in the indicator menu. You are required to report on all KPIs that align with associated funded activities. For all non-KPI indicators in the menu, note that you DO NOT need to report on all indicators within the technical areas that you support. Please only report on the indicators that are relevant to your work and leave responses blank for indicators that are not relevant to your work.

Partner Name

- A Global Healthcare Public Foundation (CPHL)
- ACONDA-VS-CI
- Addis Ababa City Administration Health Bureau (AACAHB)
- Afghanistan National Public Health Institute (ANPHI)
- Africa CDC
- African Field Epidemiology Network (AFENET)
- African Medical and Research Foundation (AMREF)
- African Society for Laboratory Medicine (ASLM)
- AFRIMS IAA
- AlertASIA
- All India Institute of Medical Sciences
- American International Health Alliance
- American Society for Microbiology (ASM)
- Amhara Regional Health Bureau
- Amref, Kenya
- Amref, Tanzania
- ANALYTIC SERVICES INC.
- Antares Foundation
- APIN Public Health Initiatives
- ASEAN+3 FETN
- Association of Public Health Laboratories (APHL)
- Baylor College of Medicine
- Baylor College of Medicine Children's Foundation, Uganda
- Biomedical Research and Training Institute
- Bizzell Group LLC
- Botswana Harvard AIDS Institute Partnership
- Brigham and Women's Hospital
- CARE International (Cooperative for Assistance and Relief Everywhere)
- Caribbean Public Health Agency (CARPHA)
- Catholic Caritas Foundation of Nigeria
- Catholic Medical Mission Board, Inc.
- CDC
- CDC Foundation
- CDC M&O
- CDC/State
- Center for Collaboration in Health (CCS)
- Center for Health Policy and Management (CHPM)
- Center for Health Solutions
- Center for International Health, Education, and Biosecurity (CIHEB)-Kenya
- Central Public Health Laboratories, MOH Uganda
- Centre for Health System Strengthening
- Centre for Infectious Disease Research, Zambia (CIDRZ)
- Centre Haitien pour le Renforcement du Systeme de Sante (CHARESS)
- Centro de Orientacion e Investigacion Integral (COIN)
- Cheikh Anta Diop University (CADU)
- Chenega
- Christian Health Association of Kenya
- Circle of Hope
- COMISCA (Secretaria General del Sistema de la Integracion Centroamericana)
- Council for Scientific & Industrial Research (CSIR)
- CRDF Global (U.S. Civilian Research and Development Foundation)
- CRS
- CSTE
- Deloitte
- Department of Defense (DOD) Naval Medical Research (NAMRU) No. 6 Interagency agreement
- Development Aid from People to People (DAPP) in Namibia
- Development Aid from People to People (DAPP) in

- Zambia
- DOS
- Eastern Deanery AIDS Relief Program
- Elizabeth Glaser Pediatric AIDS Foundation (EGPAF)
- Emergency Management Training & Consulting LLC
- Emory University
- EMPHNET
- Ethiopia Public Health Institute (EPHI)
- FHI 360
- Fiotec (Fundacao Para O Desenvolvimento Cientifico e Tecnologico em Saude)
- FSI
- FUMEC (Fundación México-Estados Unidos para la Ciencia)
- G4S
- General Department of Preventive Medicine, MOH Vietnam
- Georgetown University
- GHESKIO
- Global Health Development (GHD)
- Global Health Systems Solutions (GHSS)
- Global Implementation Solutions (GIS)
- Government of Botswana
- Guidehouse LLP
- Health Security Partners (HSP)
- Henry Jackson Foundation
- Human Sciences Research Council
- ICAP, Columbia University
- ICASS
- IERT team
- IFRC
- iMMAP
- Infectious Diseases Institute (IDI)
- INS Columbia (National Institute of Health)
- INS Mozambique (National Institute of Health)
- Institut Pasteur de Cote d'Ivoire
- Institut Pasteur, Dakar
- Institut Pasteur, Ho Chi Minh City (PIHCMC)
- Institut Pasteur, Nha Trang (PINT)
- Institut Pasteur, Tunis
- Institute of Human Virology (IHVN)
- Integrated Quality Laboratory Services (IQLS)
- International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
- International Federation of Red Cross and Red Crescent Societies (IFRC)
- International Medical Corps (IMC)
- International Organization for Migration (IOM)
- International Rescue Committee (IRC)
- IntraHealth International
- IQVIA
- IRD Vietnam
- I-TECH (International Training and Education Center for Health, University of Washington)
- ITOPPS
- Jembi Health Systems
- JHPIEGO, Johns Hopkins University
- JIC Translation
- Johns Hopkins University
- Kampala Capital City Authority
- L. Sakvarelidze National Center for Disease Control
- Lighthouse Trust
- Liverpool School of Tropical Medicine (LSTM)
- Lusaka Provincial Health Office
- LVCT Health (Liverpool VCT Care and Treatment)
- Makerere University School of Public Health
- Management and Development for Health (MDH)
- Management Sciences for Health, Inc.
- Medical Access Uganda Limited (MAUL)
- Metabiota
- Metas Solutions LLC

- Mildmay Uganda
- Ministry of Civil Affairs
- Ministry of Environmental Protection and Agriculture
- MOH Egypt
- MOH Eswatini
- MOH Ethiopia
- MOH Georgia
- MOH Guyana
- MOH Haiti
- MOH Indonesia (Kementerian Kesehatan RI)
- MOH Laos
- MOH Lesotho
- MOH Liberia
- MOH Macedonia
- MOH Mexico
- MOH Moldova
- MOH Mongolia
- MOH Morocco
- MOH Nepal
- MOH Paraguay
- MOH Russia
- MOH Rwanda
- MOH Senegal
- MOH Sierra Leone
- MOH Tanzania
- MOH Togo
- MOH Trinidad & Tobago
- MOH Tunisia
- MOH Ukraine
- MOH Vietnam, General Department of Preventive Medicine (GDPM)
- MOH Zambia
- MOHSS Namibia
- MOPH Thailand
- MOPHS Kenya
- Namibia Institute of Pathology (NIP)
- National Center of Expertise
- National Health Laboratory Service
- National Institute for Communicable Diseases (NICD)
- National Institute for Medical Research (NIMR)
- National Institute of Epidemiology, Chennai
- National Institute of Hygiene and Epidemiology (NIHE)
- National Registration Bureau
- National School of Public Health (SPH), Angola
- Nigeria CDC
- Nii Grippa Minzdrava Rossii FGBU
- Noguchi Memorial Institute for Medical Research
- OH
- Ohio State University (OSU)
- OIE
- ORISE
- Oromia Regional Health Bureau
- PAHO
- Pakistan National Institute of Health (NIH)
- Partners in Health (PIH)
- Patan Academy of Health Sciences
- PATH
- Population Services International (PSI)
- Potentia Namibia Recruitment Consultancy
- Pro-Health International
- Public Health Center of the MOH of Ukraine
- Public Health Institute (PHI)
- Rakai Health Sciences Program (RHSP)
- Research Triangle Institute (RTI)
- RI Technologies Limited
- Riders for Health-Liberia
- Rwanda Biomedical Center
- SAFETYNET
- Save the Children

- SECID Foundation (Southeast European Center for Surveillance and Control of Infectious Diseases)
- Secretaria de Estado de Salud Pública y Asistencia Social, Dominican Republic
- SHARE India
- Southern Nations Nationalities & Peoples Regional State Health Bureau, Ethiopia
- Southern Provincial Health Office, Zambia
- Strategic Innovative Solutions (SIS)
- Tanaq
- Task Force for Global Health
- Tây Nguyên Institute of Hygiene and Epidemiology (TIHE), Vietnam
- TEPHINET
- The AIDS Support Organisation (TASO)
- The Regents of the University of California, San Francisco (UCSF)
- The Trustees of Columbia University in the City of New York
- Totally Joined for Achieving Collaborative Techniques (TJFACT)
- Translation Excellence, Inc.
- Trust for Health System Planning and Development
- Uganda Prison Services
- Uganda Virus Research Institute (UVRI)
- UNICEF
- Universidad del Valle de Guatemala (UVG)
- Universidad Peruana Cayetano Heredia
- University of Hong Kong
- University of Maryland, Baltimore (UMB)
- University of Oslo
- University of Washington
- University Research Co (URC)
- University Teaching Hospital, Zambia
- Vanderbilt University Medical Center
- Vietnam Administration for Medical Services (VAMS)
- Vietnam National Lung Hospital
- Voluntary Health Services
- Washington State University (WSU)
- WHO (World Health Organization)
- WHO Somalia
- Wits Health Consortium
- My Organization is not Listed Here

Please specify the name of your organization if it is not in the dropdown list above.

Country

If multiple countries are included under an umbrella CoAg, please select "Multi-Country"

If CoAg is not country-specific, please select "Global"

- AFGHANISTAN
- ÅLAND ISLANDS
- ALBANIA
- ALGERIA
- AMERICAN SAMOA
- ANDORRA
- ANGOLA
- ANGUILLA
- ANTARCTICA
- ANTIGUA AND BARBUDA
- ARGENTINA
- ARMENIA
- ARUBA
- AUSTRALIA
- AUSTRIA
- AZERBAIJAN
- BAHAMAS
- BAHRAIN
- BANGLADESH
- BARBADOS
- BELARUS
- BELGIUM
- BELIZE
- BENIN
- BERMUDA
- BHUTAN
- BOLIVIA (PLURINATIONAL STATE OF)
- BONAIRE, SINT EUSTATIUS AND SABA
- BOSNIA AND HERZEGOVINA
- BOTSWANA
- BOUVET ISLAND
- BRAZIL
- BRITISH INDIAN OCEAN TERRITORY
- BRUNEI DARUSSALAM
- BULGARIA
- BURKINA FASO
- BURUNDI
- CABO VERDE
- CAMBODIA
- CAMEROON
- CANADA
- CAYMAN ISLANDS
- CENTRAL AFRICAN REPUBLIC
- CHAD
- CHILE
- CHINA
- CHRISTMAS ISLAND
- COCOS (KEELING) ISLANDS
- COLOMBIA
- COMOROS
- CONGO (THE DEMOCRATIC REPUBLIC OF THE)
- CONGO
- COOK ISLANDS
- COSTA RICA
- CÔTE D'IVOIRE
- CROATIA
- CUBA
- CURAÇAO
- CYPRUS
- CZECHIA
- DENMARK
- DJIBOUTI
- DOMINICA
- DOMINICAN REPUBLIC
- ECUADOR
- EGYPT
- EL SALVADOR
- EQUATORIAL GUINEA
- ERITREA

- ESTONIA
- ESWATINI
- ETHIOPIA
- FALKLAND ISLANDS
- FAROE ISLANDS
- FIJI
- FINLAND
- FRANCE
- FRENCH GUIANA
- FRENCH POLYNESIA
- FRENCH SOUTHERN TERRITORIES
- GABON
- GAMBIA
- GEORGIA
- GERMANY
- GHANA
- GIBRALTAR
- GREECE
- GREENLAND
- GRENADA
- GUADELOUPE
- GUAM
- GUATEMALA
- GUERNSEY
- GUINEA
- GUINEA-BISSAU
- GUYANA
- HAITI
- HEARD ISLAND AND MCDONALD ISLANDS
- HOLY SEE
- HONDURAS
- HONG KONG
- HUNGARY
- ICELAND
- INDIA
- INDONESIA
- IRAN (ISLAMIC REPUBLIC OF)
- IRAQ
- IRELAND
- ISLE OF MAN
- ISRAEL
- ITALY
- JAMAICA
- JAPAN
- JERSEY
- JORDAN
- KAZAKHSTAN
- KENYA
- KIRIBATI
- KOREA (THE DEMOCRATIC PEOPLE'S REPUBLIC OF)
- KOREA (THE REPUBLIC OF)
- KUWAIT
- KYRGYZSTAN
- LAO PEOPLE'S DEMOCRATIC REPUBLIC
- LATVIA
- LEBANON
- LESOTHO
- LIBERIA
- LIBYA
- LIECHTENSTEIN
- LITHUANIA
- LUXEMBOURG
- MACAO
- MADAGASCAR
- MALAWI
- MALAYSIA
- MALDIVES
- MALI
- MALTA
- MARSHALL ISLANDS
- MARTINIQUE

- MAURITANIA
- MAURITIUS
- MAYOTTE
- MEXICO
- MICRONESIA (FEDERATED STATES OF)
- MOLDOVA (THE REPUBLIC OF)
- MONACO
- MONGOLIA
- MONTENEGRO
- MONTSERRAT
- MOROCCO
- MOZAMBIQUE
- MYANMAR
- NAMIBIA
- NAURU
- NEPAL
- NETHERLANDS
- NEW CALEDONIA
- NEW ZEALAND
- NICARAGUA
- NIGER
- NIGERIA
- NIUE
- NORFOLK ISLAND
- NORTH MACEDONIA
- NORTHERN MARIANA ISLANDS
- NORWAY
- OMAN
- PAKISTAN
- PALAU
- PALESTINE, STATE OF
- PANAMA
- PAPUA NEW GUINEA
- PARAGUAY
- PERU
- PHILIPPINES
- PITCAIRN
- POLAND
- PORTUGAL
- PUERTO RICO
- QATAR
- RÉUNION
- ROMANIA
- RUSSIAN FEDERATION
- RWANDA
- SAINT BARTHÉLEMY
- SAINT HELENA, ASCENSION AND TRISTAN DA CUNHA
- SAINT KITTS AND NEVIS
- SAINT LUCIA
- SAINT MARTIN (FRENCH PART)
- SAINT PIERRE AND MIQUELON
- SAINT VINCENT AND THE GRENADINES
- SAMOA
- SAN MARINO
- SAO TOME AND PRINCIPE
- SAUDI ARABIA
- SENEGAL
- SERBIA
- SEYCHELLES
- SIERRA LEONE
- SINGAPORE
- SINT MAARTEN (DUTCH PART)
- SLOVAKIA
- SLOVENIA
- SOLOMON ISLANDS
- SOMALIA
- SOUTH AFRICA
- SOUTH GEORGIA AND THE SOUTH SANDWICH ISLANDS
- SOUTH SUDAN
- SPAIN
- SRI LANKA

- SUDAN
 - SURINAME
 - SVALBARD AND JAN MAYEN
 - SWEDEN
 - SWITZERLAND
 - SYRIAN ARAB REPUBLIC
 - TAIWAN (PROVINCE OF CHINA)
 - TAJIKISTAN
 - TANZANIA, THE UNITED REPUBLIC OF
 - THAILAND
 - TIMOR-LESTE
 - TOGO
 - TOKELAU
 - TONGA
 - TRINIDAD AND TOBAGO
 - TUNISIA
 - TURKEY
 - TURKMENISTAN
 - TURKS AND CAICOS ISLANDS
 - TUVALU
 - UGANDA
 - UKRAINE
 - UNITED ARAB EMIRATES
 - UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND
 - UNITED STATES MINOR OUTLYING ISLANDS
 - UNITED STATES OF AMERICA
 - URUGUAY
 - UZBEKISTAN
 - VANUATU
 - VENEZUELA (BOLIVARIAN REPUBLIC OF)
 - VIET NAM
 - VIRGIN ISLANDS (BRITISH)
 - VIRGIN ISLANDS (U.S.)
 - WALLIS AND FUTUNA
 - WESTERN SAHARA
 - YEMEN
 - ZAMBIA
 - ZIMBABWE
 - MULTI-COUNTRY
 - GLOBAL
 - OTHER
 - Unknown
- (Reminder: Please submit one report per country per CoAg.)

You have selected "Multi-Country". Are you reporting indicator metrics for a CoAg that is affiliated with multiple countries under an umbrella agreement?

- Yes
- No

If you select "Yes", please confirm this selection with your Project Officer. If you select "No", please return to the previous question and select another option.

If multi-country, which country or countries does this report reflect?

If possible, please submit one report per country per CoAg.

(Reminder: Please submit one report per country per CoAg.)

You have selected "Global". Are you reporting indicator metrics for a CoAg that is not affiliated with any single country, but instead, provided funding for global uses?

- Yes
 No

If you select "Yes", please confirm this selection with your Project Officer. If you select "No", please return to the previous question and select another option.

You have selected "Other". Please specify here.

CoAg #

- GH000746
- GH000096
- NU14GH001238
- NU19GH001627
- NU2GGH001271
- NU2GGH001307
- NU2GGH001309
- NU2GGH001319
- NU2GGH001351
- NU2GGH001353
- NU2GGH001355
- NU2GGH001391
- NU2GGH001399
- NU2GGH001433
- NU2GGH001438
- NU2GGH001457
- NU2GGH001462
- NU2GGH001488
- NU2GGH001490
- NU2GGH001598
- NU2GGH001609
- NU2GGH001617
- NU2GGH001620
- NU2GGH001630
- NU2GGH001632
- NU2GGH001643
- NU2GGH001663
- NU2GGH001676
- NU2GGH001717
- NU2GGH001721
- NU2GGH001752
- NU2GGH001809
- NU2GGH001860
- NU2GGH001885
- NU2GGH001914
- NU2GGH001919
- NU2GGH001920
- NU2GGH001923
- NU2GGH001924
- NU2GGH001926
- NU2GGH001934
- NU2GGH001935
- NU2GGH001936
- NU2GGH001937
- NU2GGH001939
- NU2GGH001941
- NU2GGH001943
- NU2GGH001944
- NU2GGH001947
- NU2GGH001948
- NU2GGH001949
- NU2GGH001957
- NU2GGH001962
- NU2GGH001970
- NU2GGH001972
- NU2GGH001976
- NU2GGH001977
- NU2GGH001978
- NU2GGH001979
- NU2GGH001980
- NU2GGH001981
- NU2GGH001984
- NU2GGH001989
- NU2GGH001990
- NU2GGH001991
- NU2GGH001992
- NU2GGH001993
- NU2GGH001995
- NU2GGH001999

- NU2GGH002000
- NU2GGH002001
- NU2GGH002002
- NU2GGH002003
- NU2GGH002005
- NU2GGH002008
- NU2GGH002009
- NU2GGH002010
- NU2GGH002021
- NU2GGH002022
- NU2GGH002024
- NU2GGH002027
- NU2GGH002032
- NU2GGH002033
- NU2GGH002034
- NU2GGH002038
- NU2GGH002040
- NU2GGH002045
- NU2GGH002046
- NU2GGH002052
- NU2GGH002054
- NU2GGH002058
- NU2GGH002059
- NU2GGH002060
- NU2GGH002064
- NU2GGH002065
- NU2GGH002066
- NU2GGH002072
- NU2GGH002090
- NU2GGH002091
- NU2GGH002093
- NU2GGH002094
- NU2GGH002095
- NU2GGH002098
- NU2GGH002100
- NU2GGH002104
- NU2GGH002106
- NU2GGH002108
- NU2GGH002111
- NU2GGH002123
- NU2GGH002131
- NU2GGH002132
- NU2GGH002140
- NU2GGH002145
- NU2GGH002147
- NU2GGH002148
- NU2GGH002152
- NU2GGH002153
- NU2GGH002156
- NU2GGH002157
- NU2GGH002162
- NU2GGH002171
- NU2GGH002174
- NU2GGH002175
- NU2GGH002177
- NU2GGH002182
- NU2GGH002183
- NU2GGH002198
- NU2GGH002201
- NU2GGH002202
- NU2GGH002203
- NU2GGH002211
- NU2GGH002214
- NU2GGH002215
- NU2GGH002216
- NU2GGH002219
- NU2GGH002221
- NU2GGH002225
- NU2GGH002226
- NU2GGH002230
- NU2GGH002234

- NU2GGH002235
- NU2GGH002236
- NU2GGH002244
- NU2GGH002250
- NU2GGH002251
- NU2GGH002255
- NU2GGH002264
- NU2GGH002266
- NU2GGH002277
- NU2GGH002279
- NU2GGH002280
- NU2GGH002281
- NU2GGH002285
- NU2GGH002286
- NU2GGH002288
- NU2GGH002291
- NU2GGH002293
- NU2GGH002294
- NU2GGH002296
- NU2GGH002301
- NU2GGH002302
- NU2GGH002303
- NU2GGH002304
- NU2GGH002308
- NU2GGH002309
- NU2GGH002312
- NU2GGH002316
- NU2GGH002335
- NU2GGH002336
- NU2GGH002338
- NU2GGH002341
- NU2GGH002344
- NU2GGH002345
- NU2GGH002351
- NU2GGH002352
- NU2GGH002356
- NU2GGH002358
- NU2GGH002372
- NU2HGH000001
- NU2HGH000002
- NU2HGH000003
- NU2HGH000004
- NU2HGH000005
- NU2HGH000006
- NU2HGH000007
- NU2HGH000008
- NU2HGH000009
- NU2HGH000010
- NU2HGH000011
- NU2HGH000015
- NU2HGH000016
- NU2HGH000017
- NU2HGH000018
- NU2HGH000020
- NU2HGH000021
- NU2HGH000022
- NU2HGH000023
- NU2HGH000024
- NU2HGH000025
- NU2HGH000026
- NU2HGH000027
- NU2HGH000028
- NU2HGH000029
- NU2HGH000030
- NU2HGH000031
- NU2HGH000032
- NU2HGH000033
- NU2HGH000034
- NU2HGH000035
- NU2HGH000036
- NU2HGH000037

- NU2HGH000038
- NU2HGH000039
- NU2HGH000040
- NU2HGH000041
- NU2HGH000042
- NU2HGH000043
- NU2HGH000044
- NU2HGH000045
- NU2HGH000046
- NU2HGH000047
- NU2HGH000048
- NU2HGH000049
- NU2HGH000050
- NU2HGH000051
- NU2HGH000053
- NU2HGH000054
- NU2HGH000056
- NU2HGH000057
- NU2HGH000058
- NU2HGH000059
- NU2HGH000060
- NU2HGH000061
- NU2HGH000062
- NU2HGH000064
- NU2HGH000065
- NU2HGH000066
- NU2HGH000067
- NU2HGH000069
- NU2HGH000072
- NU2HGH000073
- NU2HGH000074
- NU2HGH000075
- NU2HGH000076
- NU2HGH000077
- NU2HGH000078
- NU2HGH000079
- NU2HGH000080
- NU2HGH000082
- NU2HGH000088
- NU2HGH000090
- NU2HGH000091
- NU2HGH000094
- NU2HGH000097
- NU2HGH000098
- NU2RGH001906
- NU2RGH001914
- NU2RGH001916
- NU38OT000297
- NU3HCK000001
- NU3HCK000002
- NU3HCK000006
- NU3HCK000010
- NU3HCK000013
- NU3HCK000018
- NU50CK000493
- NU50CK000494
- NU50CK000495
- NU51P000848
- NU51P000850
- NU51P000851
- NU51P000852
- NU51P000853
- NU51P000854
- NU51P000855
- NU51P000856
- NU51P000857
- NU51P000859
- NU51P000861
- NU51P000871
- NU51P000873
- NU51P000882

- NU51IP000883
 - NU51IP000884
 - NU51IP000890
 - NU51IP000891
 - NU51IP000892
 - NU51IP000894
 - NU51IP000895
 - NU51IP000896
 - NU51IP000897
 - NU51IP000899
 - NU51IP000901
 - NU51IP000902
 - NU51IP000903
 - NU51IP000905
 - NU51IP000906
 - NU51IP000912
 - NU51IP000914
 - NU51IP000923
 - NU51IP000926
 - NU51IP000929
 - NU51IP000930
 - NU51IP000936
 - NU51IP000937
 - NU51IP000938
 - NU51IP000939
 - NU51IP000940
 - NU51IP000941
 - NU51IP000942
 - NU60OE000104
 - NU66GH002169
 - NU66GH002171
 - NU66GH002172
 - My CoAg isn't listed here
- (Note. You may begin typing your CoAg number here to search the dropdown list.)

Please indicate your CoAg # here:

Reporting Period

- FY22 Q1&Q2 (October 1, 2021 - March 31, 2022)

Technical Area(s)

Technical Area(s) supported

- Infection Prevention and Control
- Border Health
- Community Mitigation
- Emergency Operations and Response
- Laboratory Diagnostics
- Surveillance and Epidemiology
- Vaccines
- Field Epidemiology Training Program (FETP)

Infection Prevention and Control Key Performance Indicators

Has program implementation started for Infection Prevention and Control activities? Yes
 No

Thanks for letting us know that implementation has not started for infection prevention and control activities! Please explain the reason for the delay in the Progress Report.

The following indicators are Key Performance Indicators. Implementing partners are required to report on all KPIs that align with associated funded activities. If any of the following indicators do not align with your funded activities, do not provide a response.

If no KPI in a selected technical area reflects implementing partner activities for this reporting period, there is a space in the Semi-Annual Progress report to provide a narrative description on progress towards global COVID-19 strategic objectives.

KPI 1.1.3 Number of healthcare facilities participating in CDC-supported healthcare detection and response networks _____

KPI 1.3.1 Proportion of facilities that have developed and approved procedures for conducting HCW screening, and leave from work policies and procedures for suspected or confirmed COVID-19 HCWs

(Note. Enter the numerator here.)

Numerator: Number of facilities that have developed and approved procedures for conducting HCW screening, and leave from work policies and procedures for suspected or confirmed COVID-19 HCWs

KPI 1.3.1 Denominator: Total number of facilities selected and/or supported/funded by the projects _____

KPI 1.3.1 Proportion of facilities that have developed and approved procedures for conducting HCW screening, and leave from work policies and procedures for suspected or confirmed COVID-19 HCWs (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

Infection Prevention and Control Program Implementation Indicators

1.1.1 Proportion of facilities that have an IPC focal person in place

(Note. Enter the numerator here.)

Numerator: Number of facilities that have an IPC focal person in place

1.1.1 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.1.1 Proportion of facilities that have an IPC focal person in place (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

1.1.2 Proportion of healthcare facilities providing essential services that implemented guideline-based IPC improvements

(Note. Enter the numerator here.)

Numerator: Number of healthcare facilities providing essential services that implemented guideline-based IPC improvements

1.1.2 Denominator: Total number of healthcare facilities selected and/or supported/funded by the projects

1.1.2 Proportion of healthcare facilities providing essential services that implemented guideline-based IPC improvements

(Note. Value of numerator must be less than or equal to the denominator)

1.2.1 Proportion of facilities that have developed and approved procedures for screening and triage

(Note. Enter the numerator here.)

Numerator: Number of facilities that have developed and approved procedures for screening and triage

1.2.1 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.2.1 Proportion of facilities that have developed and approved procedures for screening and triage (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

1.2.2 Proportion of facilities that received training and educational materials on screening and triage

(Note. Enter the numerator here.)

Numerator: Number of facilities that received training and educational materials on screening and triage

1.2.2 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.2.2 Proportion of facilities that received training and educational materials on screening and triage (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

1.2.3 Proportion of facilities that have designated staff to screen and triage patients

(Note. Enter the numerator here.)

Numerator: Number of facilities that have designated staff to screen and triage patients

1.2.3 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.2.3 Proportion of facilities that have designated staff to screen and triage patients (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

1.2.4 Proportion of facilities that have designated space for screening and triage

(Note. Enter the numerator here.)

Numerator: Number of facilities that have designated space for screening and triage

1.2.4 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.2.4 Proportion of facilities that have designated space for screening and triage (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

1.2.5 Proportion of facilities that have the necessary supplies and equipment to screen and triage patients

(Note. Enter the numerator here.)

Numerator: Number of facilities that have the necessary supplies and equipment to screen and triage patients

1.2.5 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.2.5 Proportion of facilities that have the necessary supplies and equipment to screen and triage patients

(Note. Value of numerator must be less than or equal to the denominator)

1.2.6 Proportion of facilities that have begun patient screening and triage

(Note. Enter the numerator here.)

Numerator: Number of facilities that have begun patient screening and triage

1.2.6 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.2.6 Proportion of facilities that have begun patient screening and triage (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

1.3.2 Proportion of facilities that received training and educational materials on HCW screening and leave from work procedures

(Note. Enter the numerator here.)

Numerator: Number of facilities that received training and educational materials on HCW screening and leave from work procedures

1.3.2 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.3.2 Proportion of facilities that received training and educational materials on HCW screening and leave from work procedures (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

1.3.3 Proportion of facilities that have designated staff to conduct and monitor HCW screening (i.e., passive, enhanced passive, and/or active)

(Note. Enter the numerator here.)

Numerator: Number of facilities that have designated staff to conduct and monitor HCW screening (i.e., passive, enhanced passive, and/or active)

1.3.3 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.3.3 Proportion of facilities that have designated staff to conduct and monitor HCW screening (i.e., passive, enhanced passive, and/or active) (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

1.3.4 Proportion of facilities that have designated space for active HCW screening

(Note. Enter the numerator here.)

Numerator: Number of facilities that have designated space for active HCW screening

1.3.4 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.3.4 Proportion of facilities that have designated space for active HCW screening (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

1.3.5 Proportion of facilities that have the necessary supplies and equipment to conduct and monitor HCW screening (i.e., passive, enhanced passive, and/or active)

(Note. Enter the numerator here.)

Numerator: Number of facilities that have the necessary supplies and equipment to conduct and monitor HCW screening (i.e., passive, enhanced passive, and/or active)

1.3.5 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.3.5 Proportion of facilities that have the necessary supplies and equipment to conduct and monitor HCW screening (i.e., passive, enhanced passive, and/or active) (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

1.3.6 Proportion of facilities that have begun HCW screening

(Note. Enter the numerator here.)

Numerator: Number of facilities that have begun HCW screening

1.3.6 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.3.6 Proportion of facilities that have begun HCW screening (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

1.4.1 Proportion of facilities that have developed and approved procedures for inpatient isolation and cohorting of suspected and confirmed COVID-19 patients

(Note. Enter the numerator here.)

Numerator: Number of facilities that have developed and approved procedures for inpatient isolation and cohorting of suspected and confirmed COVID-19 patients

1.4.1 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.4.1 Proportion of facilities that have developed and approved procedures for inpatient isolation and cohorting of suspected and confirmed COVID-19 patients (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

1.4.2 Proportion of facilities that received training and educational materials on inpatient isolation and cohorting

(Note. Enter the numerator here.)

Numerator: Number of facilities that received training and educational materials on inpatient isolation and cohorting

1.4.2 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.4.2 Proportion of facilities that received training and educational materials on inpatient isolation and cohorting (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

1.4.3 Proportion of facilities that have staffing plans in place for COVID-19 treatment and isolation units

(Note. Enter the numerator here.)

Numerator: Number of facilities that have staffing plans in place for COVID-19 treatment and isolation units

1.4.3 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.4.3 Proportion of facilities that have staffing plans in place for COVID-19 treatment and isolation units (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

1.4.4 Proportion of facilities that have designated space to isolate and cohort suspected and confirmed COVID-19 patients

(Note. Enter the numerator here.)

Numerator: Number of facilities that have designated space to isolate and cohort suspected and confirmed COVID-19 patients

1.4.4 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.4.4 Proportion of facilities that have designated space to isolate and cohort suspected and confirmed COVID-19 patients (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

1.4.5 Proportion of facilities that have the necessary supplies and equipment to isolate and cohort suspected and confirmed COVID-19 patients

(Note. Enter the numerator here.)

Numerator: Number of facilities that have the necessary supplies and equipment to isolate and cohort suspected and confirmed COVID-19 patients

1.4.5 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.4.5 Proportion of facilities that have the necessary supplies and equipment to isolate and cohort suspected and confirmed COVID-19 patients (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

1.4.6 Proportion of facilities that have begun to isolate or cohort suspected and confirmed COVID-19 patients

_____ (Note. Enter the numerator here.)

Numerator: Number of facilities that have begun to isolate or cohort suspected and confirmed COVID-19 patients

1.4.6 Denominator: Total number of facilities selected and/or supported/funded by the projects

1.4.6 Proportion of facilities that have begun to isolate or cohort suspected and confirmed COVID-19 patients

_____ (Note. Value of numerator must be less than or equal to the denominator)

Additional Comments

Border Health Key Performance Indicators

Has program implementation started for Border Health activities? Yes No

Thanks for letting us know that implementation has not started for border health activities! Please explain the reason for the delay in the Progress Report.

The following indicators are Key Performance Indicators. Implementing partners are required to report on all KPIs that align with associated funded activities. If any of the following indicators do not align with your funded activities, do not provide a response.

If no KPI in a selected technical area reflects implementing partner activities for this reporting period, there is a space in the Semi-Annual Progress report to provide a narrative description on progress towards global COVID-19 strategic objectives.

2.1.3 Proportion of POE health staff trained on SOPs for identification (signs and symptoms), notification, and illness response, including for COVID-19, among travelers in the last six months

_____ (Note. Enter the numerator here.)

Numerator: Number of POE health staff trained on SOPs for identification (signs and symptoms), notification, and illness response, including for COVID-19, among travelers in the last six months

2.1.3 Denominator: Number of health staff at priority POE sites that trained staff on SOPs for identification (signs and symptoms), notification, and illness response, including for COVID-19, among travelers in the last six months

2.1.3 Proportion of POE health staff trained on SOPs for identification (signs and symptoms), notification, and illness response, including for COVID-19, among travelers in the last six months (autocalculated)

_____ (Note. Value of numerator must be less than or equal to the denominator)

2.1.9 Proportion of POE that can demonstrate capacity for identification, notification, assessment, and referral of an ill traveler to health care through response to simulated or real-life events in the last year

_____ (Note. Enter the numerator here.)

Numerator: Number of POE selected and/or supported/funded by the projects that demonstrate capacity for identification, notification, assessment, and referral of an ill traveler to health care through response to simulated or real-life events in the last year

2.1.9 Denominator: Total number of POE selected and/or supported/funded by the projects

2.1.9 Proportion of POE that can demonstrate capacity for identification, notification, assessment, and referral of an ill traveler to health care through response to simulated or real-life events in the last year

(Note. Value of numerator must be less than or equal to the denominator)

2.5.4 Number of priority geographic areas in which data on population mobility patterns has been collected in the last six months

2.5.5 Proportion of public health emergency responses that utilized population mobility pattern data to inform public health interventions and/or public health emergency responses (i.e., identified POE for capacity building, identified HCF for strengthened surveillance) within the last six months

(Note. Enter the numerator here.)

Numerator: Number of public health emergency responses that utilized population mobility pattern data to inform public health interventions and/or public health emergency responses (i.e., identified POE for capacity building, identified HCF for strengthened surveillance) within the last six months

2.5.5 Denominator: Total number of public health emergency responses

2.5.5 Proportion of public health emergency responses that utilized population mobility pattern data to inform public health interventions and/or public health emergency responses (i.e., identified POE for capacity building, identified HCF for strengthened surveillance) within the last six months

(Note. Value of numerator must be less than or equal to the denominator)

2.6.1 Proportion of neighboring countries included in formalized agreements and procedures for public health information sharing with neighboring countries

(Note. Enter the numerator here.)

Numerator: Number of neighboring countries included in formalized agreements and procedures for public health information sharing with neighboring countries

2.6.1 Denominator: Total Number of neighboring countries

2.6.1 Proportion of neighboring countries included in formalized agreements and procedures for public health information sharing with neighboring countries (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

Border Health Program Implementation Indicators

2.1.1 Proportion of priority POE with multisectoral SOPs in place for identification (signs and symptoms), notification, and illness response, including for COVID-19, among travelers

_____ (Note. Enter the numerator here.)

Numerator: Number of priority POE with multisectoral SOPs in place for identification (signs and symptoms), notification, and illness response, including for COVID-19, among travelers

2.1.1. Denominator: Number of priority POE that have been identified by public health leadership for capacity building

2.1.1 Proportion of priority POE with multisectoral SOPs in place for identification (signs and symptoms), notification, and illness response, including for COVID-19, among travelers (autocalculated)

_____ (Value of numerator must be less than or equal to the denominator)

2.1.2 Among those with SOPs above: Proportion of priority POE with health- and non-health staff trained on SOPs for identification (signs and symptoms), notification, and illness response, including for COVID-19, among travelers in the last six months

_____ (Note. Enter the numerator here.)

Numerator: Among those with SOPs above: Number of priority POE with health- and non-health staff trained on SOPs for identification (signs and symptoms), notification, and illness response, including for COVID-19, among travelers in the last six months

2.1.2 Denominator: Among those with SOPs above: Total Number of priority POE with multisectoral SOPs in place for identification (signs and symptoms), notification, and illness response, including COVID-19, among travelers

2.1.2 Among those with SOPs above: Proportion of priority POE with health- and non-health staff trained on SOPs for identification (signs and symptoms), notification, and illness response, including for COVID-19, among travelers in the last six months (autocalculated)

_____ (Value of numerator must be less than or equal to the denominator)

2.1.4 Proportion of POE non-health staff trained on SOPs for identification (signs and symptoms), notification, and illness response, including for COVID-19, among travelers in the last six months

_____ (Note. Enter the numerator here.)

Numerator: Number of POE non-health staff trained on SOPs for identification (signs and symptoms), notification, and illness response, including for COVID-19, among travelers in the last six months

2.1.4 Denominator: Number of non-health staff at priority POE sites that trained staff on SOPs for identification (signs and symptoms), notification, and illness response, including for COVID-19, among travelers in the last six months

2.1.4 Proportion of POE non-health staff trained on SOPs for identification (signs and symptoms), notification, and illness response, including for COVID-19, among travelers in the last six months (autocalculated)

(Value of numerator must be less than or equal to the denominator)

2.1.5 Number of priority POE that can demonstrate capacity for coordinated response in identification, notification, assessment, and referral of an ill traveler to health care through response to simulated or real-life events in the last year

2.1.6 Number of priority POE that have conducted AARs following a simulated or real-life event and implemented corrective actions to address gaps identified

2.1.7 Proportion of non-health POE personnel who have been trained on approved procedures and guidance in enforcing public health regulations applicable to points of entry, travel, and the transport of goods across international borders

(Note. Enter the numerator here.)

Numerator: Number of non-health POE personnel (e.g., immigrations, customs, law enforcement, etc.) who were selected and/or supported/funded by the projects who have been trained on approved procedures and guidance

2.1.7 Denominator: Number of non-health POE personnel (e.g., immigrations, customs, law enforcement, etc.) who were selected and/or supported/funded by the projects

2.1.7 Proportion of non-health POE personnel who have been trained on approved procedures and guidance in enforcing public health regulations applicable to points of entry, travel, and the transport of goods across international borders

(Value of numerator must be less than or equal to the denominator)

2.1.8 Proportion of POE where staff have been trained on approved procedures in enforcing public health regulations applicable to points of entry, travel, and the transport of goods across international borders

(Note. Enter the numerator here.)

Numerator: Number of POE selected and/or supported/funded by the projects that have trained all relevant staff on approved procedures in enforcing public health regulations applicable to points of entry, travel, and the transport of goods across international borders

2.1.8 Denominator: Number of POE selected and/or supported/funded by the projects

2.1.8 Proportion of POE where staff have been trained on approved procedures in enforcing public health regulations applicable to points of entry, travel, and the transport of goods across international borders

(Value of numerator must be less than or equal to the denominator)

2.2.1 Proportion of priority POE that have identified areas to isolate ill travelers for assessment and while waiting for transfer to a healthcare facility

(Note. Enter the numerator here.)

Numerator: Number of priority POE sites that have identified areas to isolate ill travelers for assessment and while waiting for transfer to a healthcare facility

2.2.1 Denominator: Total number of priority POE sites

2.2.1 Proportion of priority POE that have identified areas to isolate ill travelers for assessment and while waiting for transfer to a healthcare facility (autocalculated)

(Value of numerator must be less than or equal to the denominator)

2.2.2 Proportion of priority POE with sufficient equipment (e.g., PPE, thermometers, forms, job-aids, handwashing stations, decontamination and disinfection supplies) or the supply chain to receive sufficient equipment to identify, notify, and respond to communicable disease illness among travelers for one month

(Note. Enter the numerator here.)

Numerator: Number of priority POE with sufficient equipment (e.g., PPE, thermometers, forms, job-aids, handwashing stations, decontamination and disinfection supplies) or the supply chain to receive sufficient equipment to identify, notify, and respond to communicable disease illness among travelers for one month

2.2.2 Denominator: Total number of priority POE sites

2.2.2 Proportion of priority POE with sufficient equipment (e.g., PPE, thermometers, forms, job-aids, handwashing stations, decontamination and disinfection supplies) or the supply chain to receive sufficient equipment to identify, notify, and respond to communicable disease illness among travelers for one month (autocalculated)

(Value of numerator must be less than or equal to the denominator)

2.3.1 Proportion of priority POE that implement personal protective measures (e.g., handwashing, wearing face coverings, social distancing) for staff and travelers according to developed SOPs

(Note. Enter the numerator here.)

Numerator: Number of priority POE that implement personal protective measures (e.g., handwashing, wearing face coverings, social distancing) for staff and travelers according to developed SOPs

2.3.1 Denominator: Total number of priority POE

2.3.1 Proportion of priority POE that implement personal protective measures (e.g., handwashing, wearing face coverings, social distancing) for staff and travelers according to developed SOPs (autocalculated)

(Value of numerator must be less than or equal to the denominator)

2.3.2 Proportion of priority POE that are routinely cleaning and disinfecting surfaces for SARS-CoV-2

Numerator: Number of priority POE that are routinely cleaning and disinfecting surfaces for SARS-CoV-2

(Note. Enter the numerator here.)

2.3.2 Denominator: Total number of priority POE

2.3.2 Proportion of priority POE that are routinely cleaning and disinfecting surfaces for SARS-CoV-2

(Value of numerator must be less than or equal to the denominator)

2.4.1 Proportion of priority POE disseminating risk communication materials tailored for travelers in appropriate languages

Numerator: Number of priority POE disseminating risk communication materials tailored for travelers in appropriate languages

(Note. Enter the numerator here.)

2.4.1 Denominator: Total number of priority POE

2.4.1 Proportion of priority POE disseminating risk communication materials tailored for travelers in appropriate languages (autocalculated)

(Value of numerator must be less than or equal to the denominator)

2.4.2 Proportion of priority POE with staff trained on providing risk communication to travelers within the last six months

Numerator: Number of priority POE with staff trained on providing risk communication to travelers within the last six months

(Note. Enter the numerator here.)

2.4.2 Denominator: Total number of priority POE

2.4.2 Proportion of priority POE with staff trained on providing risk communication to travelers within the last six months (autocalculated)

(Value of numerator must be less than or equal to the denominator)

2.4.3 Proportion of POE staff trained on providing risk communication to travelers within the last six months

(Note. Enter the numerator here.)

Numerator: Number of POE staff trained on providing risk communication to travelers within the last six months

2.4.3 Denominator: Total number of POE staff

2.4.3 Proportion of POE staff trained on providing risk communication to travelers within the last six months (autocalculated)

(Value of numerator must be less than or equal to the denominator)

2.5.1 Number of staff trained on collecting data on population mobility patterns in the last six months

2.5.2 Number of staff trained on analyzing and summarizing data collected on population mobility patterns in the last six months

2.5.3 Number of key informant interviews (KII) or focus group discussions (FGD) conducted to collect data on population mobility patterns in the last six months

2.5.6 There are protocols and/or standard operating procedures that govern use of border health data and information systems.

Yes
 No

2.5.7 Proportion of POEs with border health personnel trained on the use of established border health data and information systems according to established SOPs

(Note. Enter the numerator here.)

Numerator: Number of POEs selected and/or supported/funded by the projects with border health personnel trained on the use of established border health data and information systems according to established SOPs

2.5.7 Denominator: Total number of POEs selected and/or supported/funded by the projects

2.5.7 Proportion of POEs with border health personnel trained on the use of established border health data and information systems according to established SOPs

(Value of numerator must be less than or equal to the denominator)

2.5.8 Proportion of POEs with border health personnel who demonstrate use of established border health data and information systems according to established SOPs

_____ (Note. Enter the numerator here.)

Numerator: Number of POEs that were selected and/or supported/funded by the projects with border health personnel who demonstrate use of established border health data and information systems according to established SOPs

2.5.8 Denominator: Total number of POEs that were selected and/or supported/funded by the projects

2.5.8 Proportion of POEs with border health personnel who demonstrate use of established border health data and information systems according to established SOPs

_____ (Value of numerator must be less than or equal to the denominator)

2.6.2 Proportion of sub-national administrative levels that have shared contact information with neighboring countries within the last six months

_____ (Note. Enter the numerator here.)

Numerator: Number of sub-national administrative levels that have shared contact information with neighboring countries within the last six months

2.6.2 Denominator: Total Number of sub-national administrative levels

2.6.2 Proportion of sub-national administrative levels that have shared contact information with neighboring countries within the last six months (autocalculated)

_____ (Value of numerator must be less than or equal to the denominator)

2.6.3 Proportion of sub-national administrative levels routinely sharing public health information with neighboring countries within the last six months

_____ (Note. Enter the numerator here.)

Numerator: Number of sub-national administrative levels routinely sharing public health information with neighboring countries within the last six months

2.6.3 Denominator: Total Number of sub-national administrative levels

2.6.3 Proportion of sub-national administrative levels routinely sharing public health information with neighboring countries within the last six months (autocalculated)

_____ (Value of numerator must be less than or equal to the denominator)

2.6.4 Number of cross-border meetings at sub-national administrative level to support operationalization of agreements and procedures within the last six months

2.7.1 Support was provided to develop an operational plan that defines the roles and responsibilities of the country's border health authority

Yes
 No

2.7.2 Proportion of identified border health staff roles with finalized position descriptions at national, sub-national, and POE levels

(Note. Enter the numerator here.)

Numerator: Number of finalized position descriptions for identified border health staff roles at national, sub-national, and POE levels

2.7.2 Denominator: Total # of identified border health staff roles at national, sub-national, and POE levels

2.7.2 Proportion of identified border health staff roles with finalized position descriptions at national, sub-national, and POE levels

(Value of numerator must be less than or equal to the denominator)

2.7.3 Does the country have an established plan for their border health personnel training program to ensure that all border health officers can competently conduct public health operations within their jurisdiction?

Yes
 No

2.7.4 National authorities have developed procedures and guidance describing how public health regulations applicable to points of entry, travel, and the transport of goods across international borders will be enforced and have disseminated them to all applicable agencies, including at sub-national- and point of entry-levels

Yes
 No

2.7.5 Proportion of border health personnel who have been trained on approved procedures in enforcing public health regulations applicable to points of entry, travel, and the transport of goods across international borders

(Note. Enter the numerator here.)

Numerator: Number of border health personnel who were selected and/or supported/funded by the projects who have been trained on the approved procedures

2.7.5 Denominator: Total number of border health personnel who were selected and/or supported/funded by the projects

2.7.5 Proportion of border health personnel who have been trained on approved procedures in enforcing public health regulations applicable to points of entry, travel, and the transport of goods across international borders

(Value of numerator must be less than or equal to the denominator)

Additional Comments

3.4.19 Proportion of Schools and Other Institutions where adequate hand hygiene or other WASH interventions have been implemented

(Note. Value of numerator must be less than or equal to the denominator)

KPI 3.4.19 Proportion of facilities where adequate hand hygiene or other WASH interventions have been implemented

(Note. Enter the numerator here.)

Numerator: Number of Healthcare Facilities where adequate hand hygiene or other WASH interventions have been implemented

3.4.19 Denominator: Total number of Healthcare Facilities targeted and/or supported/funded by the projects

3.4.19 Proportion of Healthcare Facilities where adequate hand hygiene or other WASH interventions have been implemented

(Note. Value of numerator must be less than or equal to the denominator)

Community Mitigation Program Implementation Indicators

3.1.4a Number of COVID-19 community-based risk communications developed that focus on: faith communities, prisons, community isolation centers (CICs), schools, displaced persons and migrants, healthcare workers, elderly, or other settings

3.1.4b Number of COVID-19 community-based risk communications disseminated that focus on: faith communities, prisons, community isolation centers (CICs), schools, displaced persons and migrants, healthcare workers, elderly, or other settings

3.2.3 Number of risk mitigation strategies that have been implemented that are tailored to the needs of specific populations

3.2.4 Number of users for COVID-19 hotline

3.2.7 Proportion of frontline workers that had an increase in awareness and knowledge to plan and implement Risk Communications and Community Engagement (RCCE) interventions at various levels as determined by pre- and post- test assessment

_____ (Note. Enter the numerator here.)

Numerator: Number of frontline workers who received a higher post-test score than pre-test score on their assessment of RCCE interventions

3.2.7 Denominator: Number of frontline workers who participated in pre- and post-test assessments of RCCE interventions

3.2.7 Proportion of frontline workers that had an increase in awareness and knowledge to plan and implement Risk Communications and Community Engagement (RCCE) interventions at various levels as determined by pre- and post- test assessment

_____ (Note. Value of numerator must be less than or equal to the denominator)

3.3.1 Number of technical assistance interactions on telehealth provided to country

3.3.2 Percent of households reached for home-based care

_____ (Note. Enter the numerator here.)

Numerator: Number of households with a COVID patient in them in the catchment area visited by a CHW providing home-based care support

3.3.2 Denominator: Number of households with a COVID patient in them in the catchment area

3.3.2 Percent of households reached for home-based care (autocalculated)

_____ (Note. Value of numerator must be less than or equal to the denominator)

3.3.3 Number of people receiving home-based care monitoring

3.3.4 Percent of home-based care patients who received pulse oximetry

(Note. Enter the numerator here.)

Numerator: Number of COVID patients in the catchment area receiving home-based pulse oximetry

3.3.4 Denominator: Number of COVID patients in the catchment area visited by a CHW providing home-based care support

3.3.4 Percent of home-based care patients who received pulse oximetry (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

3.3.5 Proportion of home-based care patients with pulse oximetry requiring referral to higher level care (i.e., SpO₂ < 92%)

(Note. Enter the numerator here.)

Numerator: Number of COVID patients in the catchment area receiving home-based pulse oximetry that required a referral to higher level care (i.e., SpO₂ < 92%)

3.3.5 Denominator: Number of COVID patients in the catchment area receiving home-based pulse oximetry

3.3.5 Proportion of home-based care patients with pulse oximetry requiring referral to higher level care (i.e., SpO₂ < 92%) (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

3.3.6 Proportion of COVID-19 patients in the catchment area receiving home-based care who are followed for six months after the resolution of their COVID-19 related illness

(Note. Enter the numerator here.)

Numerator: Number of COVID-19 patients in the catchment area receiving home-based care that are followed for six months after the resolution of their illness

3.3.6 Denominator: Number of COVID-19 patients in the catchment area receiving home-based care

3.3.6 Proportion of COVID-19 patients in the catchment area receiving home-based care who are followed for six months after the resolution of their COVID-19 related illness

(Note. Value of numerator must be less than or equal to the denominator)

3.4.1 Number of hand hygiene stations installed in Communal Points (Container Based)

3.4.1 Number of hand hygiene stations installed in Communal Points (All Other)

3.4.1 Number of hand hygiene stations installed in Schools and Other Institutions (Container Based)

3.4.1 Number of hand hygiene stations installed in Schools and Other Institutions (All Other)

3.4.1 Number of hand hygiene stations installed in Healthcare Settings (Container Based)

3.4.1 Number of hand hygiene stations installed in Healthcare Settings (All Other)

3.4.2 Proportion of hand hygiene stations that are fully functional (reported separately at communal points, schools and other institutions, and healthcare settings)

(Note. Enter the numerator here.)

Numerator: Number of hand hygiene stations that are fully functional (HW: Handwashing stations with soap and water) in Communal Points (Container Based)

3.4.2 Proportion of hand hygiene stations that are fully functional in Communal Points (Container Based) (autocalculated)

(Note. Denominator is equal to the numerator entered in indicator 3.4.1. Value of numerator must be less than or equal to the denominator)

3.4.2 Proportion of hand hygiene stations that are fully functional (reported separately at communal points, schools and other institutions, and healthcare settings)

(Note. Enter the numerator here.)

Numerator: Number of hand hygiene stations that are fully functional (HW: Handwashing stations with soap and water) in Communal Points (All Other)

3.4.2 Proportion of hand hygiene stations that are fully functional in Communal Points (All Other) (autocalculated)

(Note. Denominator is equal to the numerator entered in indicator 3.4.1. Value of numerator must be less than or equal to the denominator)

3.4.2 Proportion of hand hygiene stations that are fully functional (reported separately at communal points, schools and other institutions, and healthcare settings)

(Note. Enter the numerator here.)

Numerator: Number of hand hygiene stations that are fully functional (HW: Handwashing stations with soap and water) in Schools and Other Institutions (Container Based)

3.4.2 Proportion of hand hygiene stations that are fully functional in Schools and Other Institutions (Container Based) (autocalculated)

(Note. Denominator is equal to the numerator entered in indicator 3.4.1. Value of numerator must be less than or equal to the denominator)

3.4.2 Proportion of hand hygiene stations that are fully functional (reported separately at communal points, schools and other institutions, and healthcare settings)

(Note. Enter the numerator here.)

Numerator: Number of hand hygiene stations that are fully functional (HW: Handwashing stations with soap and water) in Schools and Other Institutions (All Other)

3.4.2 Proportion of hand hygiene stations that are fully functional in Schools and Other Institutions (All Other) (autocalculated)

(Note. Denominator is equal to the numerator entered in indicator 3.4.1. Value of numerator must be less than or equal to the denominator)

3.4.2 Proportion of hand hygiene stations that are fully functional (reported separately at communal points, schools and other institutions, and healthcare settings)

(Note. Enter the numerator here.)

Numerator: Number of hand hygiene stations that are fully functional (HW: Handwashing stations with soap and water) in Healthcare Settings (Container Based)

3.4.2 Proportion of hand hygiene stations that are fully functional in Healthcare Settings (Container Based) (autocalculated)

(Note. Denominator is equal to the numerator entered in indicator 3.4.1. Value of numerator must be less than or equal to the denominator)

3.4.2 Proportion of hand hygiene stations that are fully functional (reported separately at communal points, schools and other institutions, and healthcare settings)

(Note. Enter the numerator here.)

Numerator: Number of hand hygiene stations that are fully functional (HW: Handwashing stations with soap and water) in Healthcare Settings (All Other)

3.4.2 Proportion of hand hygiene stations that are fully functional in Healthcare Settings (All Other) (autocalculated)

(Note. Denominator is equal to the numerator entered in indicator 3.4.1. Value of numerator must be less than or equal to the denominator)

3.4.3 Estimated number of beneficiaries reached through hand hygiene stations: Communal Points

3.4.3 Estimated number of beneficiaries reached through hand hygiene stations: Schools and Other Institutions

3.4.3 Estimated number of beneficiaries reached through hand hygiene stations: Healthcare Settings

3.4.4 Number of sanitation facilities installed or improved (CB: Container-based) in Communal Points (Container Based)

3.4.4 Number of sanitation facilities installed or improved (CB: Container-based) in Communal Points (All Other) _____

3.4.4 Number of sanitation facilities installed or improved (CB: Container-based) in Schools and Other Institutions (Container Based) _____

3.4.4 Number of sanitation facilities installed or improved (CB: Container-based) in Schools and Other Institutions (All Other) _____

3.4.4 Number of sanitation facilities installed or improved (CB: Container-based) in Healthcare Settings (Container Based) _____

3.4.4 Number of sanitation facilities installed or improved (CB: Container-based) in Healthcare Settings (All Other) _____

3.4.5 Number of sanitation facilities that are actively managed at Communal Points _____

3.4.5 Number of sanitation facilities that are actively managed in Schools and Other Institutions _____

3.4.5 Number of sanitation facilities that are actively managed in Healthcare Settings _____

3.4.6 Total number of water points/water systems installed and/or improved at Communal Points _____

3.4.6 Total number of water points/water systems installed and/or improved in Schools and Other Institutions _____

3.4.6 Total number of water points/water systems installed and/or improved in Healthcare Settings (HCFs) _____

3.4.7 Number of liters of locally-produced ABHR produced _____

3.4.8 Number of liters of locally-produced ABHR distributed at Communal Points _____

3.4.8 Number of liters of locally-produced ABHR distributed in Schools and Other Institutions _____

3.4.8 Number of liters of locally-produced ABHR distributed in Healthcare Settings _____

3.4.9 Number of community-level handwashing and hygiene messaging activities conducted _____

3.4.10 Estimated number of persons reached with community-level handwashing and hygiene messaging _____

3.4.11 Number of hygiene kits distributed _____

3.4.12 Number of households receiving hygiene kit(s) _____

3.4.13 Number of handwashing and hygiene messaging activities conducted at the household level _____

3.4.14 Percent of staff trained that are active in case investigation or contact tracing during reporting period _____

(Note. Enter the numerator here.)

Numerator: Number of staff trained that are active in case investigation or contact tracing during reporting period

3.4.14 Denominator: Total number of staff trained _____

3.4.14 Percent of staff trained that are active in case investigation or contact tracing during reporting period (autocalculated) _____

(Note. Value of numerator must be less than or equal to the denominator)

3.4.15 Number of community sensitization/education meetings or advocacy products (e.g., radio program/messages, text messaging campaigns, etc.) held or disseminated for contact tracing _____

3.4.16 Number of periodic (daily or weekly) situational reports that include case investigation and contact tracing key indicator data _____

3.4.17 Percent of the following indicators reported on in situational report out of: 1) Number and percentage of clients interviewed within 6 days of symptom onset, 2) Number and percentage of clients interviewed within a day from report to health authority during review period, 3) Median number of days from assignment of investigations to interview during review period, 4) Median number of days from initiation/assignment of contact to notification during review period, 5) Percent of cases that originate in contact list

(Note. Enter the numerator here.)

Numerator: Number of the following indicators reported on in situational report out of: 1) Number and percentage of clients interviewed within 6 days of symptom onset; 2) Number and percentage of clients interviewed within a day from report to health authority during review period; 3) Median number of days from assignment of investigations to interview during review period; 4) Median number of days from initiation/assignment of contact to notification during review period; and 5) Percent of cases that originate in contact list

3.4.17 Percent of the following indicators reported on in situational report out of: 1) Number and percentage of clients interviewed within 6 days of symptom onset; 2) Number and percentage of clients interviewed within a day from report to health authority during review period; 3) Median number of days from assignment of investigations to interview during review period; 4) Median number of days from initiation/assignment of contact to notification during review period; and 5) Percent of cases that originate in contact list (autocalculated)

(Note. Value of numerator must be less than or equal to 5)

3.5.1 Proportion of facilities utilizing multi-month (3 months or more) dispensing (MMD) of prescriptions

(Note. Enter the numerator here.)

Numerator: Number of facilities utilizing multi-month (3 months or more) dispensing (MMD) of prescriptions

3.5.1 Denominator: Total number of facilities the implementing partner is working with on MMD

3.5.1 Proportion of facilities utilizing multi-month (3 months or more) dispensing (MMD) of prescriptions (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

3.5.2 Number of patients receiving 3-months or more of medication

3.5.3 Proportion of facilities implementing multi-month dispensing (MMD) for TB preventative treatment (TPT)

(Note. Enter the numerator here.)

Numerator: Number of facilities implementing multi-month dispensing (MMD) for TB Preventative Treatment (TPT)

3.5.3 Denominator: Total number of facilities that were selected and/or supported/funded by the projects _____

3.5.3 Proportion of facilities implementing multi-month dispensing (MMD) for TB preventative treatment (TPT)

(Note. Value of numerator must be less than or equal to the denominator)

3.5.4: Proportion of facilities implementing multi-month dispensing (MMD) for TB Treatment

(Note. Enter the numerator here.)

Numerator: Number of facilities implementing multi-month dispensing (MMD) for TB Treatment

3.5.4. Denominator: Total number of facilities that were selected and/or supported/funded by the projects _____

3.5.4: Proportion of facilities implementing multi-month dispensing (MMD) for TB Treatment

(Note. Value of numerator must be less than or equal to the denominator)

3.5.5: Proportion of facilities implementing bi-directional TB and COVID-19 screening

(Note. Enter the numerator here.)

Numerator: Number of facilities implementing bi-directional TB and COVID-19 screening

3.5.5 Denominator: Total number of facilities that were selected and/or supported/funded by the projects _____

3.5.5 Proportion of facilities implementing bi-directional TB and COVID-19 screening

(Note. Value of numerator must be less than or equal to the denominator)

3.5.6 Proportion of facilities that have standardized algorithm and SOPs established for bi-directional screening for COVID-19 and TB in relevant clinical settings

(Note. Enter the numerator here.)

Numerator: Number of facilities with a standardized algorithm and SOPs for bi-directional screening

3.5.6 Denominator: Total number of facilities that were selected and/or supported/funded by the projects _____

3.5.6 Proportion of facilities that have standardized algorithm and SOPs established for bi-directional screening for COVID-19 and TB in relevant clinical settings

(Note. Value of numerator must be less than or equal to the denominator)

3.5.7: Proportion of facilities that have conducted training on algorithms and SOPs for bi-directional screening for COVID-19 and TB

(Note. Enter the numerator here.)

Numerator: Number of facilities that have conducted training on standardized algorithm and SOPs

3.5.7 Denominator: Total number of facilities that were selected and/or supported/funded by the projects _____

3.5.7: Proportion of facilities that have conducted training on algorithms and SOPs for bi-directional screening for COVID-19 and TB

(Note. Value of numerator must be less than or equal to the denominator)

Additional Comments

Emergency Operations and Response Key Performance Indicators

Has program implementation started for Emergency Operations and Response activities? Yes
 No

Thanks for letting us know that implementation has not started for emergency operations and response activities! Please explain the reason for the delay in the Progress Report.

The following indicators are Key Performance Indicators. Implementing partners are required to report on all KPIs that align with associated funded activities. If any of the following KPIs do not align with your funded activities, do not provide a response.

If no KPI in a selected technical area reflects implementing partner activities for this reporting period, there is a space in the Semi-Annual Progress report to provide a narrative description on progress towards global COVID-19 strategic objectives.

KPI 4.1.5 Number of CDC trained PHEM fellows currently being utilized in country _____

KPI 4.1.18 Number of trained RRT responders who served as responders in the field or in response coordination roles that were trained/supported by the country's emergency coordination entity (e.g., NPHI, PHEOC, or country equivalent) and served in this function for the COVID-19 response _____

KPI 4.1.19 The country's emergency coordination entity (e.g., PHEOC or country equivalent) has an emergency RCCE coordination pillar/group Yes
 No

Emergency Operations and Response Program Implementation Indicators

4.1.1 Number of workshops/training on EMSI, RRT management and responder readiness, RCCE, and/or PHEM _____

4.1.2 Number of participants trained in emergency management systems integration _____

4.1.3 Number of multidisciplinary participants trained for COVID-19 rapid response teams _____

4.1.4 Number of participants trained in RCCE _____

4.1.6 Number of policies, plans, processes, and SOPs established for EMSI, RRT, RCCE and/or PHEM _____

4.1.7 Number of COVID-19 specific trainings/workshops/webinars organized and/or supported by their NPHI or country equivalent _____

4.1.8 Number of participants in COVID-19 specific trainings/workshops/webinars organized and/or supported by their NPHI or country equivalent _____

4.1.9 COVID-19 strategic response and recovery plan has been developed at the country level with support of the country's emergency coordination entity (e.g., NPHI, PHEOC, or country equivalent) Yes No

4.1.10 Country has capacity for EOC activation within 48 hours of detection of a public health event Yes No

4.1.11 Country has capacity for RRT deployment within 48 hours of detection of a public health event Yes No

4.1.12 A national RCCE strategy and operations plan has been established or updated and approved Yes No

4.1.13 A national RCCE training package has been established and approved in the last 6 months Yes No

4.1.14: A national RCCE training package has been implemented within 6 months of approval Yes No

4.1.15: Number of public health leaders, government officials, or media spokespersons trained in RCCE Yes No

4.1.16 Mean change in awareness and knowledge of public health leaders and community, government officials, or spokespersons to plan and implement RCCE interventions as determined by pre-and post-test assessment

(Enter average pre-test score here)

4.1.16a Average Pre-Test Assessment Score

4.1.16 Mean change in awareness and knowledge of public health leaders and community, government officials, or spokespersons to plan and implement RCCE interventions as determined by pre-and post-test assessment

_____ (Enter average post-test score here)

4.1.16b Average Post-Test Assessment Score

4.1.16: Mean change in awareness and knowledge of public health leaders and community, government officials, or spokespersons to plan and implement RCCE interventions as determined by pre-and post-test assessment

4.1.17 Number of strategic behavior change/risk communication messages and/or products developed for target population(s)

4.2.1 Number of emergency operation centers (EOCs) established and/or strengthened with the associated systems within national public health institutes and at sub-national levels

4.2.2 Does the partner provide support for recovery operations planning and implementation? (Select one)

Yes
 No

4.2.3: COVID-19 strategic response and recovery plan has been implemented at the country level with support of the country's emergency coordination entity (e.g., NPHI, PHEOC, or country equivalent)

Yes
 No

4.2.4: Number of new sub-national PHEOCs operational for COVID-19

4.2.5 A national RCCE strategy and operations plan has been used and/or tested in an exercise or response with key response stakeholders within the first year after being approved

Yes
 No

4.3.1 Number of information sharing systems or mechanisms established within national public health institutes/ Ministry of Health and among key stakeholders

4.3.2 Number of platforms developed for integrated data sharing at the national and sub-national levels

Additional Comments

Laboratory Diagnostics Key Performance Indicators

Has program implementation started for Laboratory Diagnostics activities? Yes No

Thanks for letting us know that implementation has not started for laboratory diagnostics activities! Please explain the reason for the delay in the Progress Report.

The following indicators are Key Performance Indicators. Implementing partners are required to report on all KPIs that align with associated funded activities. If any of the following indicators do not align with your funded activities, do not provide a response.

If no KPI in a selected technical area reflects implementing partner activities for this reporting period, there is a space in the Semi-Annual Progress report to provide a narrative description on progress towards global COVID-19 strategic objectives.

KPI 5.1.3 Number of participants trained by training area for testing _____

KPI 5.1.3 Number of participants trained by training area for biosafety _____

KPI 5.1.3 Number of participants trained by training area for laboratory quality _____

KPI 5.1.3 Number of participants trained by training area for biosecurity _____

KPI 5.3.9a Number of last-mile (in-country) deliveries of laboratory goods for general reagents financially supported and completed under appropriate transport and storage conditions _____

KPI 5.3.9b Number of last-mile (in-country) deliveries of laboratory goods for lab consumables financially supported and completed under appropriate transport and storage conditions _____

KPI 5.3.9c Number of last-mile (in-country) deliveries of laboratory goods for equipment financially supported and completed under appropriate transport and storage conditions _____

KPI 5.3.9d Number of last-mile (in-country) deliveries of laboratory goods for diagnostic kits - molecular financially supported and completed under appropriate transport and storage conditions _____

KPI 5.3.9e Number of last-mile (in-country) deliveries of laboratory goods for diagnostic kits - antigen financially supported and completed under appropriate transport and storage conditions _____

KPI 5.3.9f Number of last-mile (in-country) deliveries of laboratory goods for diagnostic kits - antibody financially supported and completed under appropriate transport and storage conditions _____

Laboratory Diagnostics Program Implementation Indicators

5.1.1 Number of training tools developed for testing

5.1.1 Number of training tools developed for biosafety

5.1.1 Number of training tools developed for laboratory quality

5.1.1 Number of training tools developed for biosecurity

5.1.1 Of the specified training tools above, indicate what training material was developed? (Select all that apply)

- Fact Sheets
 Slide Presentations
 Job-aids
 Manuals
 Translations
 Webinars
 Case Studies
 Validation
 Templates
 Questionnaires
 Other

5.1.2 Number of training of trainer (TOT) sessions held by training area for testing

5.1.2 Number of training of trainer (TOT) sessions held by training area for biosafety

5.1.2 Number of training of trainer (TOT) sessions held by training area for laboratory quality

5.1.2 Number of training of trainer (TOT) sessions held by training area for biosecurity

5.1.4 Number of supported sites that received non-training related technical assistance

5.1.5 Number of staff documented as receiving laboratory training with certificate of completion for testing

5.1.5 Number of staff documented as receiving laboratory training with certificate of completion for biosafety

5.1.5 Number of staff documented as receiving laboratory training with certificate of completion for laboratory quality

5.1.5 Number of staff documented as receiving laboratory training with certificate of completion for biosecurity

5.1.6 Number of staff certified as competent in testing

5.1.6 Number of staff certified as competent in biosafety

5.1.6 Number of staff certified as competent in laboratory quality _____

5.1.6 Number of staff certified as competent in biosecurity _____

5.2.1 Number of rounds of proficiency testing performed for supported sites conducting COVID-19 testing in molecular _____

5.2.1 Number of rounds of proficiency testing performed for supported sites conducting COVID-19 testing in antibody _____

5.2.1 Number of rounds of proficiency testing performed for supported sites conducting COVID-19 testing in antigen _____

5.2.3 Number of supported sites participating in External Quality Assurance Programs (EQAP) _____

5.2.3a Of the supported sites participating in EQAP, specify the types of testing performed (Select all that apply)

- Molecular
 Antibody
 Antigen
-

5.2.4 Number of supported sites with laboratory staff participating in approved PT programs _____

5.2.4.a Of the supported sites participating in approved PT, specify the types of testing performed (Select all that apply)

- Molecular
 Antibody
 Antigen
-

5.2.5 Number of supported sites requesting QA/QC technical assistance _____

5.2.5.a Of the supported sites requesting QA/QC technical assistance, select the type of sites (Select all that apply)

- Laboratory
 Point-of-Care
-

5.2.6 Number of supported sites participating in EQAP that achieved successful/passing score _____

5.2.7 Number of supported sites participating in EQAP that achieved a score of 100% _____

5.2.8 Number of supported sites that participated in EQAP and did not achieve a successful result for every sample in the panel (qualitative) or scored less than 100% (quantitative) _____

5.2.9 Number of supported sites participating in EQAP and/or approved PT programs and did not achieve a successful result that documented what corrective action would be, or was, taken to address unsuccessful results _____

5.2.10 Number of supported sites participating in EQAP that achieved less than 100% score in more than one consecutive round _____

5.2.12 Number of supported sites participating in approved PT programs that achieved a score of 100% _____

5.2.14 Number of supported sites that participated in approved proficiency testing and did not achieve a successful result for every sample in the PT panel (qualitative) or scored less than 100% (quantitative) that documented what corrective action would be, or was, taken to address unsuccessful results _____

5.2.16 Number of supported sites using protocols authorized for US FDA EUA and/or WHO EUL _____

5.2.16.a Of the supported sites using protocols authorized for US FDA EUA and/or WHO EUL, specify the type of site(s) (Select all that apply)

- Laboratory
 Point-of-Care

5.2.17 Number of supported sites using protocols not authorized for US FDA EUA and/or WHO EUL _____

5.2.17.a Of the supported sites using protocols not authorized for US FDA EUA and/or WHO EUL, specify the type of site (Select all that apply)

- Laboratory
 Point-of-Care

5.2.18 Number of supported sites that have COVID-19 related testing in their QMS _____

5.2.18.a Of the supported sites that have COVID-19 related testing in their QMS, specify the type of site (Select all that apply)

- Laboratory
 Point-of-Care

5.2.19 Number of supported sites that are tracking quality indicators associated with SARS-CoV-2 testing _____

5.2.19.a Of the supported sites that are tracking quality indicators associated with SARS-CoV-2 testing, specify the type of site (Select all that apply)

- Laboratory
 Point-of-Care

5.2.20 Number of supported sites that have COVID-19 bio-risk management policies, physical security controls and/or biological specimen inventories _____

5.2.20.a Of the supported sites that have COVID-19 bio-risk management policies, physical security controls and/or biological specimen inventories, specify the type of site (Select all that apply)

- Laboratory
 Point-of-Care

5.2.21 Number of SARS-CoV-2 testing sites performing biological risk assessments for all COVID-19 related tests _____

5.2.21.a Of the SARS-CoV-2 testing sites performing biological risk assessments for all COVID-19 related tests, specify the type of site (Select all that apply)

- Laboratory
 Point-of-Care

5.2.22 Have you supported laboratories in the supported country to implement routine specimen referral systems and transport networks with defined and tracked turnaround time targets?

- Yes
 No

5.2.23 Number of laboratories that have on-site evidence of technical and biosafety standard operating procedures specific to COVID-19 testing

5.2.24 Number of data or digital systems developed or maintained

5.2.25 Number of laboratory staff that participated in SARS-CoV-2 proficiency testing (PT)

5.2.26 Number of laboratory staff participating in approved PT programs that achieved successful/passing score

5.2.27 Number of laboratory staff that participated in approved PT programs and did not achieve a successful/passing score

5.2.28 Number of test kits validated for SARS-CoV-2

5.3.1a Number of laboratory supply orders for general reagents submitted needing cost estimate creation

 (Note. Do NOT input financial information here, just the number of orders)

5.3.1b Number of laboratory supply orders for lab consumables submitted needing cost estimate creation

 (Note. Do NOT input financial information here, just the number of orders)

5.3.1c Number of laboratory supply orders for equipment submitted needing cost estimate creation

 (Note. Do NOT input financial information here, just the number of orders)

5.3.1d Number of laboratory supply orders for diagnostic kits - molecular submitted needing cost estimate creation

 (Note. Do NOT input financial information here, just the number of orders)

5.3.1e Number of laboratory supply orders for diagnostic kits - antigen submitted needing cost estimate creation

 (Note. Do NOT input financial information here, just the number of orders)

5.3.1f Number of laboratory supply orders for diagnostic kits - antibody submitted needing cost estimate creation

(Note. Do NOT input financial information here, just the number of orders)

5.3.2a Number of laboratory supply orders for general reagents requested that had cost estimates provided

(Note. Do NOT input financial information here, just the number of orders)

5.3.2b Number of laboratory supply orders for lab consumables requested that had cost estimates provided

(Note. Do NOT input financial information here, just the number of orders)

5.3.2c Number of laboratory supply orders for equipment requested that had cost estimates provided

(Note. Do NOT input financial information here, just the number of orders)

5.3.2d Number of laboratory supply orders for diagnostic kits - molecular requested that had cost estimates provided

(Note. Do NOT input financial information here, just the number of orders)

5.3.2e Number of laboratory supply orders for diagnostic kits - antigen requested that had cost estimates provided

(Note. Do NOT input financial information here, just the number of orders)

5.3.2f Number of laboratory supply orders for diagnostic kits - antibody requested that had cost estimates provided

(Note. Do NOT input financial information here, just the number of orders)

5.3.3a Number of laboratory supply orders for general reagents with cost estimates finalized

(Note. Do NOT input financial information here, just the number of orders)

5.3.3b Number of laboratory supply orders for lab consumables with cost estimates finalized

(Note. Do NOT input financial information here, just the number of orders)

5.3.3c Number of laboratory supply orders for equipment with cost estimates finalized

(Note. Do NOT input financial information here, just the number of orders)

5.3.3d Number of laboratory supply orders for diagnostic kits - molecular with cost estimates finalized

(Note. Do NOT input financial information here, just the number of orders)

5.3.3e Number of laboratory supply orders for diagnostic kits - antigen with cost estimates finalized

(Note. Do NOT input financial information here, just the number of orders)

5.3.3f Number of laboratory supply orders for diagnostic kits - antibody with cost estimates finalized

(Note. Do NOT input financial information here, just the number of orders)

5.3.4a Number of laboratory supply orders for general reagents committed

(Note. Do NOT input financial information here, just the number of orders)

5.3.4b Number of laboratory supply orders for lab consumables committed

(Note. Do NOT input financial information here, just the number of orders)

5.3.4c Number of laboratory supply orders for equipment committed

(Note. Do NOT input financial information here, just the number of orders)

5.3.4d Number of laboratory supply orders for diagnostic kits - molecular committed

(Note. Do NOT input financial information here, just the number of orders)

5.3.4e Number of laboratory supply orders for diagnostic kits - antigen committed

(Note. Do NOT input financial information here, just the number of orders)

5.3.4f Number of laboratory supply orders for diagnostic kits - antibody committed

(Note. Do NOT input financial information here, just the number of orders)

5.3.5a Number of laboratory supply orders for general reagents procured

5.3.5b Number of laboratory supply orders for lab consumables procured

5.3.5c Number of laboratory supply orders for equipment procured

5.3.5d Number of laboratory supply orders for diagnostic kits - molecular procured

5.3.5e Number of laboratory supply orders for diagnostic kits - antigen procured

5.3.5f Number of laboratory supply orders for diagnostic kits - antibody procured

5.3.6a Number of POE deliveries of laboratory goods for general reagents completed _____

5.3.6b Number of POE deliveries of laboratory goods for lab consumables completed _____

5.3.6c Number of POE deliveries of laboratory goods for equipment completed _____

5.3.6d Number of POE deliveries of laboratory goods for diagnostic kits - molecular completed _____

5.3.6e Number of POE deliveries of laboratory goods for diagnostic kits - antigen completed _____

5.3.6f Number of POE deliveries of laboratory goods for diagnostic kits - antibody completed _____

5.3.7a Number of POE deliveries of laboratory goods for general reagents completed under appropriate transport and storage conditions _____

5.3.7b Number of POE deliveries of laboratory goods for lab consumables completed under appropriate transport and storage conditions _____

5.3.7c Number of POE deliveries of laboratory goods for equipment completed under appropriate transport and storage conditions _____

5.3.7d Number of POE deliveries of laboratory goods for diagnostic kits - molecular completed under appropriate transport and storage conditions _____

5.3.7e Number of POE deliveries of laboratory goods for diagnostic kits - antigen completed under appropriate transport and storage conditions _____

5.3.7f Number of POE deliveries of laboratory goods for diagnostic kits - antibody completed under appropriate transport and storage conditions _____

5.3.8a Number of last-mile (in-country) deliveries of laboratory goods for general reagents financially supported and completed _____

5.3.8b Number of last-mile (in-country) deliveries of laboratory goods for lab consumables financially supported and completed _____

5.3.8c Number of last-mile (in-country) deliveries of laboratory goods for equipment financially supported and completed _____

5.3.8d Number of last-mile (in-country) deliveries of laboratory goods for diagnostic kits - molecular financially supported and completed _____

5.3.8e Number of last-mile (in-country) deliveries of laboratory goods for diagnostic kits - antigen financially supported and completed _____

5.3.8f Number of last-mile (in-country) deliveries of laboratory goods for diagnostic kits - antibody financially supported and completed _____

5.3.10 Number of consignees that received financial and/or logistics support for procurement of laboratory reagents and/or other supplies necessary to conduct laboratory testing _____

5.3.11 Number of laboratory supply orders that have reconciliation reports completed _____

5.3.12 Number of laboratories that received COVID-19 diagnostic test kits that met transport and storage requirements and were delivered within projected delivery timelines _____

Additional Comments

Surveillance and Epidemiology Key Performance Indicators

Has program implementation started for Surveillance activities? Yes
 No

Thanks for letting us know that implementation has not started for surveillance activities! Please explain the reason for the delay in the Progress Report.

The following indicators are Key Performance Indicators. Implementing partners are required to report on all KPIs that align with associated funded activities. If any of the following indicators do not align with your funded activities, do not provide a response.

If no KPI in a selected technical area reflects implementing partner activities for this reporting period, there is a space in the Semi-Annual Progress report to provide a narrative description on progress towards global COVID-19 strategic objectives.

KPI 6.1.1 Is SARS-CoV-2 testing incorporated into existing ILI, SARI or other respiratory disease sentinel surveillance [at the national and subnational level], including extension of surveillance and testing to seasons during which respiratory disease surveillance is not typically done or influenza virus is not known to circulate? (Select one) Yes
 No

KPI 6.1.7 Number of digital systems implemented for COVID-19 surveillance _____

KPI 6.2.2a Number of participants of trainings held for subnational epidemiology workforce to improve COVID-19 surveillance and contact tracing _____

KPI 6.2.2b Number of participants of trainings held for national epidemiology workforce to improve COVID-19 surveillance and contact tracing _____

KPI 6.3.2 Country received CDC implementing partner technical assistance for planning, implementation, or evaluation of COVID-19 epidemiology and surveillance activities Yes
 No

Surveillance and Epidemiology Program Implementation Indicators

6.1.2 Is technical assistance being provided to [national or subnational staff] on routinely reporting epidemiologic and virologic data on COVID-19 collected through sentinel surveillance (ILI, SARI, ARI) and/or non-sentinel surveillance sites (Select one)

- Yes
 No

6.1.3 Extent to which technical assistance has been provided to country for weekly surveillance reporting on the weekly number of new confirmed cases, deaths and hospitalizations, including in HCWs, disaggregated by age, sex, and geographic region (Select one)

- Not Started
 Planned
 Provided but reporting has not started
 Provided and reporting is ongoing

6.1.8: Country includes COVID-19 case data in their routine, national disease reporting systems

- Yes
 No

6.1.9 Country includes COVID-19 case data in their national weekly and/or monthly epidemiology-surveillance bulletins

- Yes
 No

6.1.10: Proportion of labs supported/funded by the projects that are connected to a LIMS with a COVID-19 module

(Note. Enter the numerator here.)

Numerator: Number of labs supported/funded by the projects that are connected to a LIMS with a COVID-19 module

6.1.10 Denominator: Number of labs that were supported/funded by the projects

6.1.10 Proportion of labs supported/funded by the projects that are connected to a LIMS with a COVID-19 module

(Note. Value of numerator must be less than or equal to the denominator)

6.1.11 Country is implementing COVID-19 surveillance program evaluations

- Yes
 No

6.1.12 Country is planning or implementing seroprevalence studies

- Yes
 No

6.1.13 Country has complete COVID-19 surveillance reporting

- Yes
 No

6.2.1a Number of trainings held for subnational epidemiology workforce to improve COVID-19 surveillance and contact tracing

6.2.1b Number of trainings held for national epidemiology workforce to improve COVID-19 surveillance and contact tracing

6.2.3 Percent of all targeted geographic areas with at least one trained personnel to improve COVID-19 surveillance and contact tracing

(Note. Enter the numerator here.)

Numerator: Number of all targeted geographic areas with at least one trained personnel to improve COVID-19 surveillance and contact tracing

6.2.3 Denominator: Number of all targeted geographic areas

6.2.3 Percent of all targeted geographic areas with at least one trained personnel to improve COVID-19 surveillance and contact tracing (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

6.2.4 Percent of subnational levels that report COVID-19 surveillance and contact tracing data

(Note. Enter the numerator here.)

Numerator: Number of subnational level public health offices/units targeted for technical assistance AND/OR training in improving COVID-19 surveillance and contact tracing

6.2.4 Denominator: Number of targeted subnational level public health offices/units that are reporting on COVID-19 surveillance and contact tracing data

6.2.4 Percentage of subnational levels that report COVID-19 surveillance and contact tracing data (autocalculated)

(Note. Value of numerator must be less than or equal to the denominator)

6.2.5 Number of trainings held on data management and epidemiologic analysis for integrated respiratory disease surveillance

6.2.6 Number of training modules developed to improve COVID-19 surveillance including data management and epidemiologic analysis for integrated respiratory disease surveillance

6.2.7 Number of participants completing training modules/program to improve COVID-19 surveillance including data management and epidemiologic analysis for integrated respiratory disease surveillance

6.2.8.a Number of national administrative levels receiving support that are utilizing Go.Data, DHIS2, CommCare, or other health information software to support and facilitate outbreak investigation including field data collection, contact tracing and visualization of chains of transmission

6.2.8.b Number of subnational administrative levels receiving support that are utilizing Go.Data, DHIS2, CommCare, or other health information software to support and facilitate outbreak investigation including field data collection, contact tracing and visualization of chains of transmission

6.2.9 Number of staff (MOH and other organizations) at local and national level dedicated to supporting and analyzing surveillance data and activities

6.3.1 Proportion of sewage samples tested positive for SARS-CoV-2

(Note. Enter the numerator here.)

Numerator: Number of sewage samples tested positive for SARS-CoV-2

6.3.1 Denominator: Number of total sewage samples tested for SARS-CoV-2

6.3.1 Proportion of sewage samples tested positive for SARS-CoV-2

(Note. Value of numerator must be less than or equal to the denominator)

6.4.1 Proportion of One Health case results reported to relevant One Health sectors

(Note. Enter the numerator here.)

Numerator: Number of One Health case results reported to relevant One Health sectors

6.4.1 Denominator: Number of One Health case results received

6.4.1: Proportion of One Health case results reported to relevant One Health sectors

(Note. Value of numerator must be less than or equal to the denominator)

6.4.2a Number of people from the Human Health sector attending One Health trainings

6.4.2b Number of people from the Animal Health sector attending One Health trainings

6.4.2c Number of people from the Environmental Health sector attending One Health trainings

Additional Comments

Vaccines

Has program implementation started for Vaccine activities? Yes
 No

Thanks for letting us know that implementation has not started for vaccine activities! Please explain the reason for the delay in the Progress Report.

The following indicators are Key Performance Indicators. Implementing partners are required to report on all KPIs that align with associated funded activities. If any of the following indicators do not align with your funded activities, do not provide a response.

If no KPI in a selected technical area reflects implementing partner activities for this reporting period, there is a space in the Semi-Annual Progress report to provide a narrative description on progress towards global COVID-19 strategic objectives.

KPI 7.1.13 Proportion of COVID-19 vaccine doses received that were delivered to CDC-supported healthcare facilities

(Note. Enter the numerator here.)

Numerator: Number of COVID-19 doses that were delivered by the implementing partner to CDC-supported healthcare facilities for administration

KPI 7.1.13 Denominator: Total number of COVID-19 vaccine doses received by implementing partner as part of project

KPI 7.1.13 Proportion of COVID-19 vaccine doses received that were delivered to CDC-supported healthcare facilities

(Note. Value of numerator must be less than or equal to the denominator)

KPI 7.1.14 Did you administer the COVID-19 vaccine?

Yes
 No

KPI 7.1.15: Number of COVID-19 vaccine doses administered

KPI 7.1.19: Number of trainings provided on planning, implementation, and monitoring COVID-19 immunization

Vaccines Program Implementation Indicators

7.1.1 Technical assistance was provided on the development of national vaccination plans (NDVPs) for COVID-19 vaccines (Select one)

- Yes
 No

7.1.2 Support was provided to conduct microplanning activities for COVID-19 vaccination (Select one)

- Yes
 No

7.1.3 Technical assistance was provided to conduct tabletop exercises for COVID-19 vaccination (Select one)

- Yes
 No

7.1.4 Technical assistance was provided on the development of vaccination plans for non-COVID-19 vaccines (Select one)

- Yes
 No

7.1.5 Were resources (e.g., funding, staff - management, oversight) expended for Intensification of Routine Immunization (IRI) activities?

- Yes
 No

7.1.6 Number of non-COVID-19 vaccine doses received

7.1.7 Number of non-COVID-19 vaccine doses distributed

7.1.8 Number of non-COVID-19 vaccine doses administered

7.1.9 Which partners or organizations collaborated on the development of the workplan for this project?

- Ministry of Health (MOH)
 CDC HQ
 CDC Country Office
 Local nonprofit organization
 NGO
 Other partner or organization (please specify)
 We do not collaborate with other partners or organizations on the development of the workplan for this project

7.1.9 Please specify the "Other" partner(s) or organization(s) with whom you collaborated on the development of the workplan for this project.

7.1.10 Please indicate the technical area/components included in the workplan for this project

- COVID-19 Vaccine Development Plan
 Vaccine Develop Plan for other pathogens (e.g., polio, yellow fever, measles, etc.)
 Vaccine Risk Communication Strategies
 Immunization information systems to track COVID-19 vaccine distribution and adverse events
 Immunization information systems to track other pathogens vaccine distribution and adverse events
 None of the above technical areas/components

7.1.11 Please indicate the target population(s) included in the workplan for this project

Faith leaders/communities
 People in prisons or jails
 People in schools
 Displaced people
 Migrants
 People in factories
 Elderly
 Other target populations (please specify)

7.1.11 Please specify the "Other" target populations

7.1.12 Number of Mobile Team vaccination sites supported during the reporting period

7.1.12 Number of Fixed Site vaccination sites supported during the reporting period

7.1.12 Number of Community-Based Outreach vaccination sites supported during the reporting period

7.1.12 Number of Mass Vaccination Sites/Campaigns supported during the reporting period

7.1.16 Number of first COVID-19 vaccine doses administered

7.1.17 Number of last recommended COVID-19 vaccine doses administered

7.1.18 Number of people who received a booster dose of an approved COVID-19 vaccine with CDC direct support

7.2.1 Support was provided for NITAG strengthening or development of vaccine policy for COVID-19 vaccines (Select one)

Yes
 No

7.2.2 Support was provided for NITAG and vaccine policy development for vaccines not including COVID-19 vaccines (Select one)

Yes
 No

7.3.1 Support was provided to establish a program to address community concerns or perceptions about COVID-19 vaccination (Select one)

Yes
 No

7.3.2 Technical assistance was provided to develop messaging and communication materials & tools for COVID-19 vaccines (Select one)

Yes
 No

7.3.3 Technical assistance was provided on the implementation of Knowledge, Attitude, and Practice (KAP) surveys and qualitative studies for COVID-19 vaccination (Select one)

Yes
 No

7.3.4 Support was provided to conduct infodemic management-related activities (Select one)

Yes
 No

7.3.5 Support was provided to establish a program to address caregivers concerns about vaccination (not specific to COVID-19 vaccines) (Select one)	<input type="radio"/> Yes <input type="radio"/> No
7.3.6 Technical assistance was provided on the development of messaging and communication materials & tools for vaccines (not specific to COVID-19 vaccines) (Select one)	<input type="radio"/> Yes <input type="radio"/> No
7.3.7 Technical assistance was provided on the implementation of Knowledge, Attitude, and Practice (KAP) surveys and qualitative studies for vaccination (not specific to COVID-19 vaccines) (Select one)	<input type="radio"/> Yes <input type="radio"/> No
7.3.8 Support was provided to conduct infodemic management-related activities (not specific to COVID-19 vaccines) (Select one)	<input type="radio"/> Yes <input type="radio"/> No
7.3.9 Number of people reached through mass media and social media with COVID-19 vaccine-related messaging	_____
7.4.1 Technical assistance was provided on development of a Vaccine Event Related Response Plan for COVID-19 vaccines (Select one)	<input type="radio"/> Yes <input type="radio"/> No
7.4.2 Technical assistance was provided on Vaccine Safety surveillance system strengthening (passive surveillance, active surveillance, or causality assessment) for COVID-19 vaccines (Select one)	<input type="radio"/> Yes <input type="radio"/> No
7.4.3 Technical assistance was provided for investigations of AEFI cases or clusters regarding COVID-19 vaccines (Select one)	<input type="radio"/> Yes <input type="radio"/> No
7.4.4 Technical assistance was provided on Vaccine Safety passive surveillance system strengthening for vaccine adverse events (not including COVID-19 vaccines) (Select one)	<input type="radio"/> Yes <input type="radio"/> No
7.4.5 Proportion of adverse events following immunization (AEFI) reports reviewed by the appropriate responsible bodies with CDC support among those submitted to country monitoring systems	_____
Numerator: Number of adverse events following immunization (AEFI) reports reviewed by the appropriate responsible bodies with CDC support	(Note. Enter the numerator here.)
7.4.5 Denominator: Number of adverse events following immunization (AEFI) reports submitted to country monitoring systems	_____
7.4.5 Proportion of adverse events following immunization (AEFI) reports reviewed by the appropriate responsible bodies with CDC support among those submitted to country monitoring systems	_____
	(Note. Value of numerator must be less than or equal to the denominator)

7.5.1 Technical assistance was provided for data management and use related to workforce development & training in preparation for the administration of COVID-19 vaccines (Select one) Yes
 No

7.5.2 Technical assistance was provided for data management and use related to workforce development & training for the national EPI program (not specific to COVID-19 vaccination) (Select one) Yes
 No

7.6.1 Technical assistance was provided for workforce development & training in preparation for the administration of COVID-19 vaccines (Select one) Yes
 No

7.6.2 Technical assistance was provided for workforce development & training for the national EPI program (not specific to COVID-19 vaccination) (Select one) Yes
 No

7.6.3 Number of staff and volunteers trained on COVID-19 vaccine-related topics _____

7.6.4 Number of staff and volunteers who are remunerated by CDC to support workload required for COVID-19 vaccine delivery in the reporting period _____

7.7.1 Technical assistance was provided to conduct evaluations of COVID-19 vaccination programs (Select one) Yes
 No

7.7.2 Technical assistance was provided to conduct evaluations of essential immunization programs and immunization campaigns (not specific to COVID-19 vaccines) (Select one) Yes
 No

Additional Comments

Field Epidemiology Training Program

Has program implementation started for FETP activities? Yes
 No

Thanks for letting us know that implementation has not started for FETP activities! Please explain the reason for the delay in the Progress Report.

8.1.1 Number of FETP trainees and graduates accessing curriculum that is adapted to integrate emergency management competencies _____

8.1.2 Number of individuals accessing online training related to FETP core content, mentor training, or COVID-19 related materials _____

8.1.3 Number of FETP trainees who are deployed, rostered or both to support COVID-19 response activities _____

8.1.4 National Public Health Institutes (NPHIs) are engaged in Emergency Operations Center (EOC) strengthening and systems integrated activities including FETPs Yes
 No
 N/A

Additional Comments